XML 107 R76.htm IDEA: XBRL DOCUMENT v3.21.2
Collaborative and Other Relationships - Collaborations (Details)
$ / shares in Units, shares in Millions, $ in Millions
 1 Months Ended 3 Months Ended 9 Months Ended
Aug. 31, 2021
USD ($)
Jun. 30, 2021
USD ($)
Nov. 30, 2020
USD ($)
$ / shares
shares
Sep. 30, 2020
USD ($)
$ / shares
Feb. 29, 2020
USD ($)
$ / shares
shares
Sep. 30, 2021
USD ($)
Jun. 30, 2021
Sep. 30, 2020
USD ($)
Jun. 30, 2020
USD ($)
Mar. 31, 2020
USD ($)
Sep. 30, 2021
USD ($)
product
Sep. 30, 2020
USD ($)
Jan. 31, 2020
USD ($)
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
Research and Development Expense (Excluding Acquired in Process Cost)           $ 702.4   $ 1,140.9     $ 1,801.7 $ 2,264.8  
Eisai                          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
Number of product candidates | product                     2    
Percentage of future development costs related to Eisai             45.00% 45.00% 45.00%        
Loss on research and development contracts terminated with Eisai                 $ 45.0        
Additional milestone payment               $ 75.0          
Eisai | BAN2401 and Elenbecestat                          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
Expense Incurred By Collaboration           118.4   75.7     $ 236.1 153.2  
Expense reflected within statements of income           59.2   37.9     118.0 76.6  
Eisai | ADUHELM                          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
Expense reflected within statements of income           0.0   0.0     45.0 33.8  
Additional milestone payment   $ 100.0       0.0   0.0     100.0 75.0  
Denali Therapeutics                          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
Global licensing collaboration agreement, amount, shares purchased (in shares)       $ 465.0                  
Global licensing collaboration agreement, shares purchased per share (in usd per share) | $ / shares       $ 34.94                  
Upfront and milestone payments made to collaborative partner                     560.0    
Global Licensing Collaboration Agreement, Research, Development, Regulatory and Commercial Milestone Payments                     1,100.0    
Research and development expense                     $ 41.3    
Samsung Bioepis                          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
Upfront and milestone payments made to collaborative partner                   $ 100.0      
Collaboration agreement term                     5 years    
Research and development expense                   $ 63.0      
Prepaid research and development expenses                         $ 37.0
Additional milestone payment           15.0              
Sage Therapeutics Inc.                          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
Global licensing collaboration agreement, amount, shares purchased (in shares)     $ 650.0                    
Global licensing collaboration agreement, shares, purchased (in shares) | shares     6.2                    
Upfront and milestone payments made to collaborative partner     $ 875.0                    
Global Licensing Collaboration Agreement, Research, Development, Regulatory and Commercial Milestone Payments     1,600.0                    
Research and development expense     $ 209.0                    
Global licensing collaboration agreement, purchase price per share (in usd per share) | $ / shares     $ 104.14                    
Sangamo Therapeutics, Inc. Agreement                          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
Global licensing collaboration agreement, amount, shares purchased (in shares)         $ 225.0                
Global licensing collaboration agreement, shares, purchased (in shares) | shares         24.0                
Global licensing collaboration agreement, shares purchased per share (in usd per share) | $ / shares         $ 9.21                
Upfront and milestone payments made to collaborative partner         $ 125.0                
Global Licensing Collaboration Agreement, Research, Development, Regulatory and Commercial Milestone Payments         2,400.0                
Global Licensing Collaboration Agreement, Payment, Selection of Targets         80.0                
Global Licensing Collaboration Agreement, Payment, Achievement of First Commercial Sale Milestones         1,900.0                
Global Licensing Collaboration Agreement, Payment, Achievement of Specific Sales Based Milestones         380.0                
Research and development expense         $ 83.0                
Term of collaboration agreement                     5 years    
Other research and discovery                          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
Research and Development Expense (Excluding Acquired in Process Cost)           7.7   38.0     $ 84.9 47.6  
InnoCare Pharma Limited (InnoCare) Agreement                          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
Upfront and milestone payments made to collaborative partner $ 125.0                        
Contingent additional milestone payment $ 812.5                        
Research and development | Eisai | ADUHELM                          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
Expense incurred by the collaboration           43.7   37.5     132.8 92.5  
Expense reflected within statements of income           24.0   20.6     73.0 50.9  
Research and development | Denali Therapeutics                          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
Expense incurred by the collaboration           8.5   0.0     27.2 0.0  
Expense reflected within statements of income           5.1   0.0     16.3 0.0  
Research and development | Sage Therapeutics Inc.                          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
Expense incurred by the collaboration           40.8   0.0     134.9 0.0  
Expense reflected within statements of income           20.4   0.0     67.3 0.0  
Research and development | UCB Pharma S.A. [Member]                          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
Expense incurred by the collaboration           16.5   10.2     49.5 35.7  
Expense reflected within statements of income           8.2   5.2     24.8 17.9  
Selling, general and administrative | Eisai | BAN2401 and Elenbecestat                          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
Expense incurred by the collaboration           5.6         15.6 6.3  
Expense reflected within statements of income           2.8         7.8 3.2  
Selling, general and administrative | Eisai | ADUHELM                          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
Expense incurred by the collaboration           154.3   90.9     391.7 158.8  
Expense reflected within statements of income           83.3   51.3     211.2 88.8  
Selling, general and administrative | Sage Therapeutics Inc.                          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
Expense incurred by the collaboration           7.4   0.0     23.2 0.0  
Expense reflected within statements of income           $ 3.7   $ 0.0     $ 11.6 $ 0.0